Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds.

Wilke, Thomas; Picker, Nils; Müller, Sabrina; Stürmlinger, Anna; Deiters, Barthold; Dittmar, Axel; Aberle, Jens; Gabler, Maximilian

Wilke, Thomas; Picker, Nils; Müller, Sabrina; Stürmlinger, Anna; Deiters, Barthold; Dittmar, Axel; Aberle, Jens; Gabler, Maximilian.

Afiliação

Wilke T; IPAM e.V., Wismar, Germany.
Picker N; Ingress-Health HWM GmbH, Wismar, Germany.
Müller S; Ingress-Health HWM GmbH, Wismar, Germany.
Stürmlinger A; Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany.
Deiters B; GWQ ServicePlus AG, Düsseldorf, Germany.
Dittmar A; IPAM e.V., Wismar, Germany.
Aberle J; Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Germany.
Gabler M; Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany.

Clinicoecon Outcomes Res ; 14: 319-332, 2022.

Article em En | MEDLINE | ID: mdl-35531480

Palavras-chave

DPP-4 inhibitors; GLP-1 receptor agonists; healthcare costs; sodium-glucose cotransporter-2 inhibitor; type 2 diabetes mellitus

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article